Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Platinum-sensitive Ovarian Cancer Clear all
Completed Phase 2 Interventional

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

NCT01033123
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BSI-201
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 17, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovarian Cancer

NCT00473954
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
EGEN-001 (phIL-12-005/PPC)
Genetic
Lead sponsor
EGEN, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • Huntsville, Alabama • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
884 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00466986
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Abraxane
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

NCT00318370
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Farletuzumab, Chemo Plus Far
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Sep 17, 2026, 4:42 AM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290
View directory record Official record
Conditions
Ovarian Cancer
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
9
States / cities
Greenbrae, California • Port Saint Lucie, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2010 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 1 Interventional

Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer

NCT00317434
View directory record Official record
Conditions
Ovarian Cancer
Interventions
lapatinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Birmingham, Alabama • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional

Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00020696
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Los Gatos, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

NCT01995188
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Bevacizumab, Carboplatin, DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 17, 2026, 4:42 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

NCT01081951
View directory record Official record
Conditions
Ovarian Cancer
Interventions
olaparib, paclitaxel, carboplatin, Drug: carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 125 Years · Female only
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
8
States / cities
Stanford, California • West Hollywood, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

NCT05914116
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole, Enzalutamide, Abiraterone
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Tucson, Arizona • Los Angeles, California • Santa Monica, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

NCT04171700
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

NCT01482715
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
6
States / cities
San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

NCT07024784
View directory record Official record
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Teaneck, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Recruiting Phase 2 Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609
View directory record Official record
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 3 Interventional

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

NCT01204749
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions
AMG 386, AMG 386 Placebo, Paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 1 Interventional

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

NCT03056833
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
ribociclib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Ronald Buckanovich
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Ann Arbor, Michigan • Bethel Park, Pennsylvania • Greensburg, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 17, 2026, 4:42 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Extension Study of the Efficacy of MORAb-003

NCT01018563
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
MORAb-003
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 17, 2026, 4:42 AM EDT
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 17, 2026, 4:42 AM EDT
Active, not recruiting Phase 3 Interventional

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT05445778
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
74
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:42 AM EDT
Withdrawn Phase 1 Interventional

Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02050009
View directory record Official record
Conditions
Ovarian Papillary Serous Carcinoma, Ovarian Serous Cystadenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer
Interventions
metformin hydrochloride, carboplatin, paclitaxel, laboratory biomarker analysis
Drug · Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 17, 2026, 4:42 AM EDT